Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 14Ovarian Neoplasms 12Triple Negative Breast Neoplasms 6Fallopian Tube Neoplasms 6Neoplasms 5Stomach Neoplasms 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Lymphoma 3Lung Neoplasms 3Colonic Neoplasms 3Breast Neoplasms, Male 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Melanoma 2Medulloblastoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Acute 2Hereditary Breast and Ovarian Cancer Syndrome 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Astrocytoma 2Zollinger-Ellison Syndrome 1Vipoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Stage IV Fallopian Tube Cancer AJCC v6 and v7 1

Interventions

pembrolizumab 26Gemcitabine 20Cisplatin 12Nivolumab 11Carboplatin 8Paclitaxel 7Docetaxel 7atezolizumab 6durvalumab 5Radiotherapy 5fludarabine 4enfortumab vedotin 4Ipilimumab 4Cyclophosphamide 4Vorinostat 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Filgrastim 3Doxorubicin 3zimberelimab 2vocimagene amiretrorepvec 2tremelimumab 2romidepsin 2poly ICLC 2infigratinib 2erdafitinib 2cc-486 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Urinary Bladder Neoplasms × veliparib × Clear all
NCT01282333 2013-07-02

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
44 enrolled
GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡